Precigen announces positive phase 1 dose escalation data for autologous prgn-3006 ultracar-t® manufactured overnight for next day infusion in relapsed or refractory acute myeloid leukemia patients

–   single infusion of ultracar-t cells with or without lymphodepletion demonstrated robust expansion and persistence in blood and bone marrow – –   prgn-3006 infusion with lymphodepletion resulted in a decrease in bone marrow blasts in 60% of heavily pre-treated patients – –   single infusion of autologous prgn-3006 cells resulted in 27% objective response rate (orr) in heavily pre-treated relapsed or refractory (r/r) acute myeloid leukemia (aml)  patients infused following lymphodepletion – –  prgn-3006 was well-tolerated with no dose-limiting toxicities (dlts) reported to date – germantown, md. , dec. 12, 2022 /prnewswire/ -- precigen, inc., a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today presented positive phase 1 dose escalation data from the ongoing phase 1/1b clinical study of prgn-3006 ultracar-t® in patients with r/r aml and higher risk myelodysplastic syndromes (mds) (clinical trial identifier: nct03927261) at the 64th american society of hematology (ash) annual meeting and exposition (abstract# 4633).
PGEN Ratings Summary
PGEN Quant Ranking